BUY Aurobindo Pharma — Goldman Sachs, 06 Nov 2026

BUYAurobindo Pharma

Aurobindo Pharma share price target & all analyst calls

byGoldman SachsHorizon: NA (inferred 1 year)6 Nov 2026via ET Now (Live)

Entry₹1,784.3Inferred

Target₹2,000

Total upside +12.09%

Stop lossNot given

CMP₹1,8001d ago

Active+0.88%+11.11%upside left 12 mo left

Follow Goldman Sachs for new calls(100% target hit, 40 closed calls)Get alerts Watch AUROPHARMA for new buy/sell callsGet alerts See 9 other Long-term calls on AUROPHARMA See 541 other Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 7 Nov, 5:25 pm IST

35 supporting10 neutral5 opposing

Supports the BUY call (35)

Long-term trend bullish — 200-day average rising over the past quarter

Technicals · trend·6 Nov · yesterday

4 other SEBI-registered advisors have active long-term BUY calls on this stock, with 2 issued in the last 14 days

Advisor consensus · same horizon·6 Nov · yesterday

Aurobindo Pharma Q2 profit rises 33%, beats estimates; declares ₹7 interim dividend

NewsCnbc-Tv18·4 Nov · 2d ago

Aurobindo Pharma Q2 Results: Profit Rises 33%, Shareholders To Get Dividend By Nov 20

NewsNdtv-Profit·4 Nov · 2d ago

Aurobindo Pharma reported Q2 FY27 consolidated revenue of INR 10,263 Cr (up 24% YoY) and net profit of INR 1,124 Cr (up 32.5% YoY). The company also declared an interim dividend of INR 7.0 per share.

NSE · Press Release·4 Nov · 2d ago

Neutral / worth noting (10)

The company transferred ownership of its Russian subsidiary, Auro Pharma LLC, between two of its wholly owned subsidiaries.

BSE · Company Update·4 Nov · 2d ago

Aurobindo Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.

NSE · Outcome of Board Meeting·4 Nov · 2d ago

Pharma Q2 Outlook: Pricing pressure, US competition to weigh on select players

NewsEt-Markets·19 Oct · 3w ago

Weighs against the BUY call (5)

3 other SEBI-registered advisors have active long-term SELL calls on this stock, with 1 issued in the last 14 days

Advisor consensus · same horizon·5 Nov · 2d ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Aurobindo Pharma

All analyst calls on Aurobindo Pharma

More from Goldman Sachs

Every call and its outcome